CN117802011B - Composite probiotics for promoting iron absorption and application thereof - Google Patents
Composite probiotics for promoting iron absorption and application thereof Download PDFInfo
- Publication number
- CN117802011B CN117802011B CN202410225116.9A CN202410225116A CN117802011B CN 117802011 B CN117802011 B CN 117802011B CN 202410225116 A CN202410225116 A CN 202410225116A CN 117802011 B CN117802011 B CN 117802011B
- Authority
- CN
- China
- Prior art keywords
- iron
- strain
- bbr60
- probiotic
- probiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 207
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 110
- 239000006041 probiotic Substances 0.000 title claims abstract description 47
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 47
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 22
- 230000001737 promoting effect Effects 0.000 title claims abstract description 19
- 239000002131 composite material Substances 0.000 title abstract description 8
- 230000000529 probiotic effect Effects 0.000 claims abstract description 20
- 241000193749 Bacillus coagulans Species 0.000 claims abstract description 9
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 8
- 238000004321 preservation Methods 0.000 claims description 16
- 206010022971 Iron Deficiencies Diseases 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 239000013589 supplement Substances 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 230000007812 deficiency Effects 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000007423 decrease Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 241001495180 Arthrospira Species 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- 102000010445 Lactoferrin Human genes 0.000 claims description 2
- 108010063045 Lactoferrin Proteins 0.000 claims description 2
- 240000007472 Leucaena leucocephala Species 0.000 claims description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 2
- 229920001100 Polydextrose Polymers 0.000 claims description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 241000222355 Trametes versicolor Species 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 230000036737 immune function Effects 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 2
- 235000021242 lactoferrin Nutrition 0.000 claims description 2
- 229940078795 lactoferrin Drugs 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000001259 polydextrose Substances 0.000 claims description 2
- 235000013856 polydextrose Nutrition 0.000 claims description 2
- 229940035035 polydextrose Drugs 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000020183 skimmed milk Nutrition 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 11
- 230000001580 bacterial effect Effects 0.000 abstract description 10
- 241000699670 Mus sp. Species 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 14
- 235000005911 diet Nutrition 0.000 description 12
- 239000011790 ferrous sulphate Substances 0.000 description 12
- 235000003891 ferrous sulphate Nutrition 0.000 description 12
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 108050000784 Ferritin Proteins 0.000 description 10
- 102000008857 Ferritin Human genes 0.000 description 10
- 238000008416 Ferritin Methods 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 8
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 8
- 150000003278 haem Chemical class 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000003213 activating effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- -1 iron ion Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 229910052564 epsomite Inorganic materials 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940054340 bacillus coagulans Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a composite probiotics for promoting iron absorption and application thereof, wherein the composite probiotics for promoting iron absorption consist of bacillus coagulans Bacillus coagulans BC strain and bifidobacterium breve Bifidobacterium breve BBr strain. The invention develops a probiotic compound mode and a strategy for improving the bioavailability of iron by organisms, namely, the BC99 strain and the BBr60 strain are combined, and the effects of the BC99 strain and the BBr60 strain on promoting iron absorption can be mutually matched, mutually promoted and synergistically enhanced, and under the condition that the using bacterial amounts are consistent, compared with the single BC99 strain or the single BBr60 strain intervening mode, the effects of the two strains on promoting iron absorption are obviously improved.
Description
Technical Field
The invention belongs to the technical field of probiotics, and relates to a composite probiotic for promoting iron absorption and application thereof.
Background
Iron is one of the first trace elements found in humans, accounting for about 0.006% of the body weight, 3-5 g of iron is contained in adults, 60-70% of which is present in hemoglobin, 3% in myoglobin, less than 1% of iron in various enzyme systems, and the remaining 26-36% is present in the form of iron transporting substances and iron reserves. Iron is an important component of hemoglobin molecules, which can absorb oxygen in the lungs, bringing it along with the blood flow to the tissue cells of the body. When iron is supplied insufficiently, the hemoglobin content in blood gradually decreases, so that iron deficiency anemia occurs, and people feel tired and weak, etc.
The most important functions ensured by the proper amount of iron in the body are related to the transport and storage of oxygen, electron transfer, regulation of redox reactions, synthesis of hormones, replication of DNA, restoration and control of cell cycle, fixation of nitrogen and antioxidation. In the case of iron deficiency, even slight discomfort may impair the normal function of the human body. Common supplementation methods are food fortification and supplementation.
Ferrous sulfate (FeSO 4) is a common oral iron supplement, but studies have shown that a less reactive adjuvant supplement (e.g., probiotics) is needed as an adjuvant and replacement in a number of Iron Deficiency Anemia (IDA) patients treated with FeSO 4 or other forms of redox active iron, which may exhibit problems caused by gastric and intestinal intolerance. The probiotics have the effect of protecting intestinal tracts, and can be used as an effective, safe and long-term dietary supplement. Further studies have shown that lactic acid produced by lactobacillus increases the dietary bioavailability of iron and that probiotics can be used as a way of optimizing the bioavailability of iron. And more studies have linked the bioavailability and absorption of iron to the microbial activity in the intestinal tract. Researchers have suggested that iron absorption and utilization may be promoted and improved by modulating intestinal microecology.
Therefore, how to provide a microbial preparation capable of effectively improving iron absorption, solving the problems of malnutrition caused by iron deficiency to patients and reducing adverse reactions in the iron supplementing process, and becoming a urgent need for solving.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a composite probiotics for promoting iron absorption and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
In a first aspect, the invention provides a composite probiotic for promoting iron absorption, which consists of a bacillus coagulans Bacillus coagulans BC strain with a preservation number of CGMCC No. 21801 and a bifidobacterium breve Bifidobacterium breve BBr strain with a preservation number of CGMCC No. 12915.
The invention creatively develops a brand-new probiotic compound mode and a brand-new strategy for improving the bioavailability of iron by organisms, namely, bacillus coagulans Bacillus coagulans BC strain and bifidobacterium breve Bifidobacterium breve BBr strain are compounded and combined, and the two strains are found to be mutually matched, mutually promoted and synergistically synergistic in the effect of promoting iron absorption, and under the condition that the using bacterial load is consistent, compared with the single BC99 strain or the single BBr60 strain intervention mode, the effect of compounding the two strains in the aspect of promoting iron absorption is obviously improved, and the method is characterized in that: raise the level of hemoglobin, ferritin and serum iron in blood and raise the level of non-heme iron in liver. Therefore, the compound probiotics have good prospect in preparing products for improving the bioavailability of the iron supplement or medicines for preventing, relieving or treating related diseases caused by iron ion deficiency. Meanwhile, both bacteria are probiotics, the product safety is high, and the resistance is not easy to generate.
The preparation method of the composite probiotics adopts a technical method conventional in the field, and can be exemplified by: activating the BC99 strain or the BBr60 strain, and then respectively inoculating the activated BC99 strain or the BBr60 strain into a culture medium for culture to obtain a culture solution; centrifuging the culture solution, and re-suspending the bacteria to obtain bacterial suspension; mixing the two bacterial suspensions according to the ratio of the viable bacteria number. Or further adding a protective agent for freeze drying to obtain a freeze-dried bacterial powder product.
Preferably, the ratio of the number of viable bacteria of the BC99 strain to the BBr60 strain is (1-10): 1, such as 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, etc., and other specific values within the numerical range can be selected, and will not be described in detail herein.
Based on the potential interaction relationship between the bacillus coagulans Bacillus coagulans BC strain and the bifidobacterium breve Bifidobacterium breve BBr strain, the invention also finds that when the two strains are compounded in the specific viable count ratio, the effect of promoting iron absorption is more remarkable.
In a second aspect, the present invention provides a probiotic for promoting iron absorption, the strain of which comprises the complex probiotic of the first aspect.
Preferably, the content of viable bacteria in the probiotics of the BC99 strain and the BBr60 strain is not lower than 1×10 8 CFU/g or 1×10 8 CFU/mL, such as 1×108 CFU/g（CFU/mL）、2×108 CFU/g（CFU/mL）、5×108 CFU/g（CFU/mL）、8×108 CFU/g（CFU/mL）、1×109 CFU/g（CFU/mL）、5×109 CFU/g（CFU/mL）、1×1010 CFU/g（CFU/mL）、1×1011 CFU/g（CFU/mL）、1×1012 CFU/g（CFU/mL）, and other specific values within the numerical range can be selected, and will not be described in detail herein.
Preferably, the formulation of the probiotic agent comprises freeze-dried powder, capsules, tablets or granules.
The formulation of the probiotics related to the invention is not limited, and comprises the most commonly used freeze-dried powder, or further prepared capsules, tablets or granules. The lyophilized powder can be prepared by the following method:
Activating the BC99 strain or the BBr60 strain, and then respectively inoculating the activated BC99 strain or the BBr60 strain into a culture medium for culture to obtain a culture solution; centrifuging the culture solution to obtain thalli; re-suspending the thalli by using a freeze-drying protective agent to obtain re-suspension; freeze-drying the heavy suspension, and mixing according to a proportion to obtain the finished product.
Preferably, the medium includes an MRS medium.
Preferably, the MRS medium includes, in concentration: 8-12 g/L of peptone, 8-12 g/L of beef extract, 15-25 g/L of glucose, 10-20 g/L of lactose, 3-7 g/L of yeast powder, 1-3 g/L、K2PO4·3H2O 2-3 g/L、MgSO4·7H2O 0.05-0.2 g/L、MnSO4 0.01-0.1 g/L、 Tween 80 0.5-2 mL/L of diammonium hydrogen citrate and 0.1-1 g/L of cysteine hydrochloride.
Preferably, the lyophilization is by vacuum freezing.
Preferably, the probiotic agent further comprises a protective agent and/or a functional auxiliary agent.
Preferably, the protective agent comprises any one or a combination of at least two of skim milk, gelatin, dextrin, acacia, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.
The functional auxiliary agent comprises any one or a combination of at least two of fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, soybean oligosaccharide, inulin, spirulina, arthrospira, coriolus versicolor polysaccharide, stachyose, polydextrose, alpha-lactalbumin or lactoferrin.
In a third aspect, the present invention provides the use of a complex probiotic according to the first aspect or a probiotic according to the second aspect in the manufacture of a product for improving the bioavailability of an iron supplement.
In a fourth aspect, the present invention provides the use of a complex probiotic according to the first aspect or a probiotic according to the second aspect in the manufacture of a medicament for the prevention, alleviation or treatment of a disease associated with iron ion deficiency.
Preferably, the related diseases caused by iron ion deficiency include iron deficiency anemia, iron deficiency arteriosclerosis, iron deficiency neuropathy or iron deficiency immune function decline.
Preferably, the medicament further comprises an iron supplement.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively develops a brand-new probiotic compound mode and a brand-new strategy for improving the bioavailability of iron by organisms, namely, bacillus coagulans Bacillus coagulans BC strain and bifidobacterium breve Bifidobacterium breve BBr strain are compounded and combined, and the two strains are found to be mutually matched, mutually promoted and synergistically synergistic in the effect of promoting iron absorption, and under the condition that the using bacterial load is consistent, compared with the single BC99 strain or the single BBr60 strain intervention mode, the effect of compounding the two strains in the aspect of promoting iron absorption is obviously improved, and the method is characterized in that: raise the level of hemoglobin, ferritin and serum iron in blood and raise the level of non-heme iron in liver. Therefore, the compound probiotics have good prospect in preparing products for improving the bioavailability of the iron supplement or medicines for preventing, relieving or treating related diseases caused by iron ion deficiency. Meanwhile, both bacteria are probiotics, the product safety is high, and the resistance is not easy to generate.
The BC99 strain related by the invention is classified and named as bacillus coagulans Bacillus coagulans, the preservation unit is China general microbiological culture Collection center, the preservation time is 2021, 2 months and 1 day, the preservation number is CGMCC No. 21801, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
The BBr60 strain related by the invention is classified and named as bifidobacterium breve Bifidobacterium breve, the preservation unit is China general microbiological culture Collection center, the preservation time is 2016, 8 and 29 days, the preservation number is CGMCC No. 12915, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
Drawings
FIG. 1 is a graph showing the results of measurement of hemoglobin levels in blood of mice in each group;
FIG. 2 is a graph showing the results of serum ferritin levels of mice in each group;
FIG. 3 is a graph showing the results of serum iron content measurement of mice in each group;
FIG. 4 is a graph showing the results of non-heme iron level measurements in the liver of each group of mice;
FIG. 5 is a graph of Chao1 index results from intestinal flora analysis of mice in each group;
FIG. 6 is a graph showing the results of shannon index analysis of intestinal flora of mice in each group.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
Peptone, beef extract, glucose, lactose, yeast powder, diammonium hydrogen citrate, K 2PO4·3H2O、MgSO4·7H2O、MnSO4, tween 80 and cysteine hydrochloride referred to in the examples below were purchased from the national pharmaceutical group chemical company.
The following examples relate to the following media:
MRS Medium (g/L): 10g/L of peptone, 10g/L of beef extract, 15g/L of glucose, 15g/L of lactose, 5g/L of yeast powder, 1mL/L of ammonium citrate 2g/L、K2PO4·3H2O 2.6g/L、MgSO4·7H2O 0.1g/L、MnSO4 0.05g/L、 Tween 80 and 0.5g/L of cysteine amino acid salt.
The BC99 strain related to the following embodiment is classified and named as bacillus coagulans Bacillus coagulans, the preservation unit is China general microbiological culture Collection center, the preservation time is 2021, 2 months and 1 day, the preservation number is CGMCC No. 21801, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
The BBr60 strain related to the following examples is classified and named as bifidobacterium breve Bifidobacterium breve, the preservation unit is China general microbiological culture Collection center (China Committee for culture Collection of microorganisms), the preservation time is 8 months and 29 days of 2016, the preservation number is CGMCC No. 12915, and the address is: the korean district North Star, beijing city, part No. 1, no. 3.
The bacterial suspensions referred to in the following examples: inoculating the required strain into MRS liquid culture medium, culturing at 37deg.C for 24 hr for activation, and continuously activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 37 ℃ for 24 hours to obtain bacterial solution; centrifuging the bacterial liquid at 6000g for 10min, and re-suspending the bacterial body by using PBS.
The experimental results data were statistically analyzed using ggplot of the R language, representing p <0.001, p <0.01, p <0.05, and ns representing no significant difference compared to CTL groups.
Examples
The compound probiotics related to the invention are explored in the embodiment as an auxiliary supplement, and the regulation and control of the hemoglobin level, the serum ferritin level and the serum iron content of a low-iron dietary mouse and the influence on the intestinal flora of the mouse are carried out on the basis of supplementing ferrous sulfate solution:
(1) Test animals
CD1 mice of 3 weeks of age were selected and purchased from Shanghai Chengxi Biotechnology Co., ltd, and have been subjected to ethical approval by the Shanghai laboratory animal research center animal ethical Committee (ethical number: 2023082001). All animals were housed under specific pathogen-free barrier conditions and were housed in independent cages for one week with adaptation. Animal experiments strictly follow the guidelines for laboratory animal care and use.
(2) Low iron diet mouse model establishment
Low iron diet mice models were induced using low iron feed (iron concentration: 3mg/kg, formulation TD 80396, harlan-Teklad, USA) for 3 weeks of feeding. All mice were given ad libitum throughout the experiment.
(3) Grouping and intervention mode for animals
After 3 weeks of feeding with the low iron diet described above, 48 mice were randomly divided into 6 groups (8 per group): a low-iron diet model group (CTL), a low-iron diet mice group treated with ferrous sulfate solution (FeSO 4), a low-iron diet mice group treated with ferrous sulfate solution and BC99 strain (FeSO 4 +bc 99), a low-iron diet mice group treated with ferrous sulfate solution and BBr60 strain (FeSO 4 +bbr 60), a low-iron diet mice group treated with ferrous sulfate solution and BC99 strain and BBr60 strain (FeSO 4 +bc99+bbr60, viable count ratio of the two strains 4:1), a low-iron diet mice group treated with ferrous sulfate solution and ATCC7050 strain (commercial bacillus coagulans strain) and BBr60 strain (FeSO 4 +atcc 7050+bbr60, viable count ratio of the two strains 4:1).
The intervention modes of each group are as follows:
CTL: low iron feed (iron concentration 3 mg/kg);
FeSO 4: treatment of low-iron feed (iron concentration 3 mg/kg) +ferrous sulfate solution (iron concentration 60mg/L,10 ml/L);
FeSO 4 +bc99: treatment of low iron feed (iron concentration 3 mg/kg) +ferrous sulphate solution (iron concentration 60mg/L,10 ml/min) +bc99 (5×10 8 CFU/day/min);
FeSO 4 +bbr60: treatment of low iron feed (iron concentration 3 mg/kg) +ferrous sulphate solution (iron concentration 60mg/L,10 ml/min) +BBr60 (5X 10 8 CFU/day);
FeSO 4 +bc99+bbr60: treatment of low iron feed (iron concentration 3 mg/kg) +ferrous sulphate solution (iron concentration 60mg/L,10 ml/min) +Bc99+BBr60 (total 5×10 8 CFU/day);
FeSO 4 +atcc7050+bbr60: treatment of low iron feed (iron concentration 3 mg/kg) +ferrous sulphate solution (iron concentration 60mg/L,10 ml/min) +ATCC7050+BBr60 (total 5×10 8 CFU/day);
Each group was given daily oral low iron feed (iron concentration: 3 mg/kg) and maintained a low iron diet. All mice were given ad libitum throughout the experiment.
(4) Index analysis
After 10 consecutive days of dosing, blood samples were collected, mice were euthanized, tissue collected, liver samples and stool samples were taken, and flash frozen in liquid nitrogen for subsequent analysis.
(4.1) Measurement of hemoglobin: after 5 μl of whole blood was added to the drapkin reagent and centrifuged at 13000 rpm min, the hemoglobin concentration was calculated from the change in optical density of 540 nm. All experimental procedures were performed strictly according to the instructions of the apparatus and kit. The results are shown in FIG. 1.
(4.2) Determination of ferritin: ferritin was determined using the Spectro ferritin MT enzyme-linked immunosorbent assay (ELISA) kit. Serum ferritin concentrations were deduced from standard curves described in the manufacturer's protocol. All experimental procedures were performed strictly according to the instructions of the apparatus and kit. The results are shown in FIG. 2.
(4.3) Serum iron content determination: serum iron concentrations were determined quantitatively by colorimetric iron determination using QuantiChrom iron determination kit (DIFE-250, bioassay Systems, USA), wavelength 590 nm. All experimental procedures were performed strictly according to the instructions of the apparatus and kit. The results are shown in FIG. 3.
Hemoglobin is the most commonly used index for diagnosing iron deficiency anemia. Serum ferritin is positively correlated with the amount of iron stored in the body, and reflects a sensitive index of iron storage change in the body. Serum iron mainly refers to iron present in serum that binds transferrin, and is reduced in response to iron levels in plasma, iron deficiency and iron deficiency anemia.
As can be seen from the results of fig. 1, 2 and 3: compared with the mice in the CTL group, the mice in the FeSO 4 group have raised contents of hemoglobin, serum ferritin and serum iron. On the basis of taking FeSO 4 at the same time, the three indexes of the mice are better than the effect of taking FeSO 4 alone after the dry pre-treatment of the probiotics BC99, BBr60 and the compound probiotics BC99+BBr60, and the effect of promoting iron absorption is optimal for the compound probiotics BC 99+BBr60.
(4.4) Liver non-heme iron level determination: liver tissue samples were weighed and homogenized with a 1 ml glass homogenizer in 10 mM NaOH-Hepes buffer (pH 7.0) using 0.15M NaCl (1:5 w/v). Non-heme iron analysis was then performed on the homogenized aliquots. Iron values are expressed as concentrations (nmol iron/mg wet weight). The results are shown in FIG. 4.
The liver is one of the most prominent iron reservoirs in the body and is also the center for iron metabolism and regulation. When iron is needed by the body, the liver can release transferrin iron to meet the iron requirements of other tissues and organs. By measuring non-heme iron levels in the liver, the storage and distribution of iron in the body can be better understood.
As can be seen from the results of fig. 4: compared with the mice in the CTL group, the non-heme iron level in the livers of the mice in the other groups is higher than that of the mice in the CTL group, and the non-heme iron level in the livers of the mice is higher than that of the mice singly taken in the FeSO 4 group and the effect of the compound probiotics BC99+BBr60 group is optimal after the compound probiotics BC99, BBr60 or the compound probiotics BC99+BBr60 are used for dry prognosis on the basis of taking FeSO 4 at the same time.
(5) Analysis of the intestinal microbiota of mice: modulation of alpha diversity of microbial communities
The V3-V4 region of the 16SrRNA gene was amplified from a mouse fecal sample by PCR using 341F and 805R primers. The PCR reaction was as follows: denaturation at 95 ℃ for 3 min, denaturation at 94 ℃ for 0.5 min, annealing at 58 ℃ for 0.5 min, denaturation at 72 ℃ for 0.5 min for 21 cycles, and final extension at 72 ℃ for 5 min. The products of the different samples were indexed and mixed in equal proportions according to the manufacturer's instructions and sequenced using the Illumina Miseq platform (2 x 300 bp).
As shown in fig. 5 and 6, the α -diversity of the microbial communities of the other groups, including the microbial abundance (expressed as the Chao1 index) and the microbial diversity (expressed as the shannon index), increased significantly compared to the CTL group, especially after the intervention of the complex probiotics bc99+bbr60 and the probiotic BC 99.
The applicant states that the technical solution of the present invention is illustrated by the above embodiments, but the present invention is not limited to the above embodiments, i.e. it does not mean that the present invention must be implemented by the above embodiments. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (7)
1. The probiotics for promoting iron absorption is characterized in that the strain in the probiotics consists of bacillus coagulans Bacillus coagulans BC strain with the preservation number of CGMCC No. 21801 and bifidobacterium breve Bifidobacterium breve BBr strain with the preservation number of CGMCC No. 12915; the ratio of the number of the viable bacteria of the BC99 strain to the BBr60 strain is (1-10): 1; the content of viable bacteria in the probiotics of the BC99 strain and the BBr60 strain is not lower than 1 multiplied by 10 8 CFU/g or 1 multiplied by 10 8 CFU/mL.
2. The probiotic agent for promoting iron absorption according to claim 1, characterized in that the formulation of the probiotic agent comprises a lyophilized powder, a capsule, a tablet or a granule;
the probiotic agent also comprises a protective agent and/or a functional auxiliary agent.
3. The probiotic agent for promoting iron absorption according to claim 2, characterized in that the protective agent comprises any one or a combination of at least two of skim milk, gelatin, dextrin, acacia, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol;
The functional auxiliary agent comprises any one or a combination of at least two of fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, soybean oligosaccharide, inulin, spirulina, arthrospira, coriolus versicolor polysaccharide, stachyose, polydextrose, alpha-lactalbumin or lactoferrin.
4. Use of a probiotic according to any one of claims 1 to 3 for the preparation of a product for improving the bioavailability of an iron supplement.
5. Use of a probiotic according to any one of claims 1 to 3 for the preparation of a medicament for the prevention, alleviation or treatment of a related disease caused by iron ion deficiency.
6. The use according to claim 5, wherein the related diseases caused by iron deficiency include iron deficiency anemia, iron deficiency arteriosclerosis, iron deficiency neuropathy or iron deficiency immune function decline.
7. The use according to claim 5, wherein the medicament further comprises an iron supplement.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410225116.9A CN117802011B (en) | 2024-02-29 | 2024-02-29 | Composite probiotics for promoting iron absorption and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410225116.9A CN117802011B (en) | 2024-02-29 | 2024-02-29 | Composite probiotics for promoting iron absorption and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117802011A CN117802011A (en) | 2024-04-02 |
| CN117802011B true CN117802011B (en) | 2024-05-17 |
Family
ID=90434955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410225116.9A Active CN117802011B (en) | 2024-02-29 | 2024-02-29 | Composite probiotics for promoting iron absorption and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117802011B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111235058A (en) * | 2020-02-20 | 2020-06-05 | 江苏微康生物科技有限公司 | Bifidobacterium breve with effects of repairing ultraviolet injury, relieving inflammation and preventing skin photoaging, and its preparation method and application |
| CN111990572A (en) * | 2020-09-03 | 2020-11-27 | 徐纯范 | Preparation method of microbial traditional Chinese medicine blood pressure-reducing beverage |
| CN112852679A (en) * | 2021-03-17 | 2021-05-28 | 武汉微康益生菌研究院有限公司 | Probiotic bacillus coagulans and application thereof |
| CN113768084A (en) * | 2021-07-29 | 2021-12-10 | 武汉微康益生菌研究院有限公司 | Noodles containing bacillus coagulans BC99 and preparation method thereof |
| CN114468306A (en) * | 2022-03-29 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | Application of bacillus coagulans BC99 in preparing colitis relieving product or immunoregulation product |
| CN114854643A (en) * | 2022-06-02 | 2022-08-05 | 微康益生菌(苏州)股份有限公司 | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof |
| CN115487214A (en) * | 2022-10-11 | 2022-12-20 | 武汉微康益生菌研究院有限公司 | Application of bacillus coagulans BC99 in relieving diarrhea-predominant irritable bowel syndrome |
-
2024
- 2024-02-29 CN CN202410225116.9A patent/CN117802011B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111235058A (en) * | 2020-02-20 | 2020-06-05 | 江苏微康生物科技有限公司 | Bifidobacterium breve with effects of repairing ultraviolet injury, relieving inflammation and preventing skin photoaging, and its preparation method and application |
| CN111990572A (en) * | 2020-09-03 | 2020-11-27 | 徐纯范 | Preparation method of microbial traditional Chinese medicine blood pressure-reducing beverage |
| CN112852679A (en) * | 2021-03-17 | 2021-05-28 | 武汉微康益生菌研究院有限公司 | Probiotic bacillus coagulans and application thereof |
| CN113768084A (en) * | 2021-07-29 | 2021-12-10 | 武汉微康益生菌研究院有限公司 | Noodles containing bacillus coagulans BC99 and preparation method thereof |
| CN114468306A (en) * | 2022-03-29 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | Application of bacillus coagulans BC99 in preparing colitis relieving product or immunoregulation product |
| CN114854643A (en) * | 2022-06-02 | 2022-08-05 | 微康益生菌(苏州)股份有限公司 | Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof |
| CN115487214A (en) * | 2022-10-11 | 2022-12-20 | 武汉微康益生菌研究院有限公司 | Application of bacillus coagulans BC99 in relieving diarrhea-predominant irritable bowel syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117802011A (en) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gopal et al. | Effects of the consumption of Bifidobacterium lactis HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects | |
| Jiang et al. | In vitro lactose fermentation by human colonic bacteria is modified by Lactobacillus acidophilus supplementation | |
| JP5409623B2 (en) | Zinc-enriched biomass, its preparation method, and probiotic products, cosmetics, dietary products and nutritional supplements containing the same | |
| Klimesova et al. | Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria | |
| CN107164295B (en) | Selenium-enriched microorganism and preparation method and application thereof | |
| CN111011867B (en) | Probiotic embedded particle and preparation method thereof | |
| JP7219801B2 (en) | Compositions and methods for preventing and/or treating vitamin B12 deficiency | |
| EP3808357A1 (en) | Composition and uses thereof | |
| TW200817508A (en) | Lactic acid bacterium for amelioration of lactose intolerance | |
| WO2023165607A1 (en) | Strain of high organic zinc enrichment bifidobacterium animalis for promoting growth and reproductive development | |
| CN115141775A (en) | Culture method for improving self efficacy and selenium enrichment capacity of probiotics and application thereof | |
| Piano et al. | Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form | |
| CN117645941A (en) | Fermented lactobacillus mucilaginosus capable of relieving hyperuricemia through simultaneous degradation of uric acid and purine nucleoside and application thereof | |
| CN117802011B (en) | Composite probiotics for promoting iron absorption and application thereof | |
| US20220193155A1 (en) | Microbial compositions and methods for greater tolerability and prolonged shelf life | |
| CN114984065B (en) | Probiotic composition for improving immunity and preparation method thereof | |
| CN113397170B (en) | Application of marine prebiotics composition for regulating human intestinal flora | |
| Hart et al. | Nutritional iron status and susceptibility to Proteus mirabilis pyelonephritis in the rat | |
| CN117778277B (en) | Composite probiotics for promoting intestinal iron ion absorption and application thereof | |
| Minuye | Aflatoxin reduction mechanism of probiotics | |
| CN115197865B (en) | Zinc-rich bifidobacterium longum capable of promoting growth and reproductive development | |
| CN117987327B (en) | Compound probiotics for resisting hepatitis B virus and application thereof | |
| US6899872B1 (en) | Absorbable dietary composition for improving the biological balance of intestinal tract flora | |
| CN117821343B (en) | Composite probiotics for regulating blood glucose metabolism and application thereof | |
| CN117987333B (en) | Composite probiotics for relieving sports fatigue and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |